Verona Hospital
Welcome,         Profile    Billing    Logout  
 7 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cesaro, simone
NCT01728155: European Low and Intermediate Risk Neuroblastoma Protocol

Completed
3
685
Europe, RoW
chemotherapy
Instituto de Investigacion Sanitaria La Fe
LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
12/22
 
HR-NBL2, NCT04221035 / 2019-001068-31: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting
3
800
Europe, RoW
Vincristine, L01CA02, Carboplatin, LO1XA02, Etoposide, L01CB01, Vindesine, L01CA03, Dacarbazine, L01AX04, Ifosfamide, Doxorubicin, L01DB01, Busulfan, L01AB01, Melphalan, L01AA03, Thiotepa, L01AC01, Radiotherapy, Dinutuximab Beta, L01XC16, Cisplatin, L01XA01, Temozolomide 100 MG, Irinotecan, Cyclophosphamid
Gustave Roussy, Cancer Campus, Grand Paris, PHRC, Solving Kids' Cancer Europe, Neuroblastoma UK, , BSPHO, Instituto de Investigación Sanitaria La Fe, Deutsche Krebshilfe
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
11/26
11/32
AIEOP-BFM ALL 2017, NCT03643276 / 2016-001935-12: Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia -

Recruiting
3
5000
Europe, RoW
Blinatumomab, Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Myocet, Dexamethasone, Doxorubicin, Etoposide, Fludarabine Phosphate, Ifosfamide, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Tioguanin, Vincristine, Vindesine, Erwinase
Martin Schrappe, Deutsche Krebshilfe e.V., Bonn (Germany)
Acute Lymphoblastic Leukemia, Pediatric
07/28
07/28
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Active, not recruiting
2
60
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
02/25
ESCORT-HU Extension, NCT04707235: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study

Active, not recruiting
N/A
2093
Europe, RoW
Hydroxycarbamide, Siklos, Hydroxyurea
Theravia, International Clinical Trials Association
Sickle Cell Disease
08/25
08/25

Download Options